Caption Management’s Viridian Therapeutics VRDN Stock Holding History

Caption Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-46,500	Closed	-$1M	–	2095
2025 Q3	$1M	Sell	46,500 -138,500	-75%	-$2.5M	0.01%	1106
2025 Q2	$2.59M	Buy	+185,000	New	+$2.51M	0.03%	642
2025 Q1	–	Sell	-516,800	Closed	-$9.91M	–	2085
2024 Q4	$9.91M	Buy	516,800 +306,400	+146%	+$6.66M	0.09%	201
2024 Q3	$4.79M	Buy	210,400 +110,700	+111%	+$1.81M	0.08%	308
2024 Q2	$1.3M	Sell	99,700 -300	-0.3%	-$4.15K	0.02%	596
2024 Q1	$1.75M	Buy	+100,000	New	+$1.94M	0.03%	574
2023 Q3	–	Sell	-60,000	Closed	-$1.43M	–	1572
2023 Q2	$1.43M	Buy	60,000 +30,000	+100%	+$769K	0.03%	584
2023 Q1	$763K	Buy	+30,000	New	+$962K	0.01%	689

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Caption Management's VRDN Position: Q1 2026 in Review

Caption Management opened a new position in Viridian Therapeutics (VRDN) in Q1 2026: 45,127 shares worth $883K. The stake represents 0.01% of the portfolio and ranks #1062 among its holdings. This is a return to the name: Caption Management previously reported a position in VRDN as recently as Q3 2025.

Caption Management first reported a position in VRDN in Q2 2022 and has held it in 8 quarters since. The position peaked at $1.09M in Q4 2024. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

Caption Management held 45,127 shares of Viridian Therapeutics worth $883K as of Q1 2026.
Viridian Therapeutics was a new Caption Management position in Q1 2026.
Viridian Therapeutics made up 0.01% of Caption Management's portfolio in Q1 2026, its #1062 holding.
Caption Management first reported a position in Viridian Therapeutics in Q2 2022 and has held it in 8 quarters since.
Caption Management's Viridian Therapeutics position peaked at $1.09M in Q4 2024.
225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.